These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
256 related articles for article (PubMed ID: 23010123)
1. Solid lipid nanoparticles as delivery systems for Gambogenic acid. Huang X; Chen YJ; Peng DY; Li QL; Wang XS; Wang DL; Chen WD Colloids Surf B Biointerfaces; 2013 Feb; 102():391-7. PubMed ID: 23010123 [TBL] [Abstract][Full Text] [Related]
2. PEGylated non-ionic surfactant vesicles as drug delivery systems for Gambogenic acid. Lin T; Fang Q; Peng D; Huang X; Zhu T; Luo Q; Zhou K; Chen W Drug Deliv; 2013; 20(7):277-84. PubMed ID: 24044645 [TBL] [Abstract][Full Text] [Related]
3. Nanosuspensions as delivery system for gambogenic acid: characterization and in vitro/in vivo evaluation. Yuan H; Li X; Zhang C; Pan W; Liang Y; Chen Y; Chen W; Liu L; Wang X Drug Deliv; 2016 Oct; 23(8):2772-2779. PubMed ID: 26292058 [TBL] [Abstract][Full Text] [Related]
4. Are nanostructured lipid carriers (NLCs) better than solid lipid nanoparticles (SLNs): development, characterizations and comparative evaluations of clotrimazole-loaded SLNs and NLCs? Das S; Ng WK; Tan RB Eur J Pharm Sci; 2012 Aug; 47(1):139-51. PubMed ID: 22664358 [TBL] [Abstract][Full Text] [Related]
5. Re-dispersible cationic solid lipid nanoparticles (SLNs) freeze-dried without cryoprotectors: characterization and ability to bind the pEGFP-plasmid. Vighi E; Ruozi B; Montanari M; Battini R; Leo E Eur J Pharm Biopharm; 2007 Sep; 67(2):320-8. PubMed ID: 17368876 [TBL] [Abstract][Full Text] [Related]
6. Formulation design, preparation and physicochemical characterizations of solid lipid nanoparticles containing a hydrophobic drug: effects of process variables. Das S; Ng WK; Kanaujia P; Kim S; Tan RB Colloids Surf B Biointerfaces; 2011 Nov; 88(1):483-9. PubMed ID: 21831615 [TBL] [Abstract][Full Text] [Related]
7. Naringenin-loaded solid lipid nanoparticles: preparation, controlled delivery, cellular uptake, and pulmonary pharmacokinetics. Ji P; Yu T; Liu Y; Jiang J; Xu J; Zhao Y; Hao Y; Qiu Y; Zhao W; Wu C Drug Des Devel Ther; 2016; 10():911-25. PubMed ID: 27041995 [TBL] [Abstract][Full Text] [Related]
8. Characterization and formulation optimization of solid lipid nanoparticles in vitamin K1 delivery. Liu CH; Wu CT; Fang JY Drug Dev Ind Pharm; 2010 Jul; 36(7):751-61. PubMed ID: 20136495 [TBL] [Abstract][Full Text] [Related]
9. Formulation and evaluation of Nimodipine-loaded solid lipid nanoparticles delivered via lymphatic transport system. Chalikwar SS; Belgamwar VS; Talele VR; Surana SJ; Patil MU Colloids Surf B Biointerfaces; 2012 Sep; 97():109-16. PubMed ID: 22609590 [TBL] [Abstract][Full Text] [Related]
10. Solid lipid nanoparticles loaded with insulin by sodium cholate-phosphatidylcholine-based mixed micelles: preparation and characterization. Liu J; Gong T; Wang C; Zhong Z; Zhang Z Int J Pharm; 2007 Aug; 340(1-2):153-62. PubMed ID: 17428627 [TBL] [Abstract][Full Text] [Related]
11. Curcumin-loaded solid lipid nanoparticles have prolonged in vitro antitumour activity, cellular uptake and improved in vivo bioavailability. Sun J; Bi C; Chan HM; Sun S; Zhang Q; Zheng Y Colloids Surf B Biointerfaces; 2013 Nov; 111():367-75. PubMed ID: 23856543 [TBL] [Abstract][Full Text] [Related]
12. Stealth tanshinone IIA-loaded solid lipid nanoparticles: effects of poloxamer 188 coating on in vitro phagocytosis and in vivo pharmacokinetics in rats. Zhang WL; Liu JP; Liu XX; Chen ZQ Yao Xue Xue Bao; 2009 Dec; 44(12):1421-8. PubMed ID: 21348419 [TBL] [Abstract][Full Text] [Related]
13. Part I: Development and optimization of solid-lipid nanoparticles using Box-Behnken statistical design for ocular delivery of gatifloxacin. Abul Kalam M; Sultana Y; Ali A; Aqil M; Mishra AK; Aljuffali IA; Alshamsan A J Biomed Mater Res A; 2013 Jun; 101(6):1813-27. PubMed ID: 23255511 [TBL] [Abstract][Full Text] [Related]
14. Emodin loaded solid lipid nanoparticles: preparation, characterization and antitumor activity studies. Wang S; Chen T; Chen R; Hu Y; Chen M; Wang Y Int J Pharm; 2012 Jul; 430(1-2):238-46. PubMed ID: 22465546 [TBL] [Abstract][Full Text] [Related]
15. Preparation and characterization of ibuprofen solid lipid nanoparticles with enhanced solubility. Potta SG; Minemi S; Nukala RK; Peinado C; Lamprou DA; Urquhart A; Douroumis D J Microencapsul; 2011; 28(1):74-81. PubMed ID: 21171818 [TBL] [Abstract][Full Text] [Related]
16. Injectable actarit-loaded solid lipid nanoparticles as passive targeting therapeutic agents for rheumatoid arthritis. Ye J; Wang Q; Zhou X; Zhang N Int J Pharm; 2008 Mar; 352(1-2):273-9. PubMed ID: 18054182 [TBL] [Abstract][Full Text] [Related]
17. Optimization of freeze-drying condition of amikacin solid lipid nanoparticles using D-optimal experimental design. Varshosaz J; Ghaffari S; Khoshayand MR; Atyabi F; Dehkordi AJ; Kobarfard F Pharm Dev Technol; 2012; 17(2):187-94. PubMed ID: 21047276 [TBL] [Abstract][Full Text] [Related]
18. Optimization of the lyophilization process for long-term stability of solid-lipid nanoparticles. Howard MD; Lu X; Jay M; Dziubla TD Drug Dev Ind Pharm; 2012 Oct; 38(10):1270-9. PubMed ID: 22235767 [TBL] [Abstract][Full Text] [Related]
19. Development of topotecan loaded lipid nanoparticles for chemical stabilization and prolonged release. Souza LG; Silva EJ; Martins AL; Mota MF; Braga RC; Lima EM; Valadares MC; Taveira SF; Marreto RN Eur J Pharm Biopharm; 2011 Sep; 79(1):189-96. PubMed ID: 21352915 [TBL] [Abstract][Full Text] [Related]
20. Effect of freeze-drying, cryoprotectants and storage conditions on the stability of secondary structure of insulin-loaded solid lipid nanoparticles. Soares S; Fonte P; Costa A; Andrade J; Seabra V; Ferreira D; Reis S; Sarmento B Int J Pharm; 2013 Nov; 456(2):370-81. PubMed ID: 24036086 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]